News
VTRS
12.45
-0.72%
-0.09
Biogen: Competing With Eli Lilly's Kisunla, Safety Gives Market Edge
Seeking Alpha · 12/30/2025 13:57
Weekly Report: what happened at VTRS last week (1222-1226)?
Weekly Report · 12/29/2025 09:39
Viatris (VTRS): Assessing Valuation After New FDA Win and Pipeline Regulatory Milestones
Simply Wall St · 12/25/2025 22:19
Viatris Inc. Stock Climbs 1.8%, Outperforms Market
Dow Jones · 12/24/2025 21:34
Early notable gainers among liquid option names on December 24th
TipRanks · 12/24/2025 14:55
How Is The Market Feeling About Viatris Inc?
Benzinga · 12/24/2025 14:00
2025 Performance Review And Future Strategy
Seeking Alpha · 12/22/2025 13:30
Viatris: Looks Cheap, But Faces Continued Contraction
Seeking Alpha · 12/22/2025 12:48
Weekly Report: what happened at VTRS last week (1215-1219)?
Weekly Report · 12/22/2025 09:39
Assessing Viatris After Its Recent Share Price Rebound and Strategy Shift
Simply Wall St · 12/20/2025 19:20
OPUS GENETICS INC - ON DEC 17, VIATRIS FILES SUPPLEMENTAL NDA WITH FDA FOR PHENTOLAMINE - SEC FILING
Reuters · 12/19/2025 21:20
Viatris Gets FDA Nod for Generic Sandostatin, Shares Regulatory Updates
NASDAQ · 12/19/2025 17:17
Viatris’ Complex Generics And Pipeline Wins Might Change The Case For Investing In Viatris (VTRS)
Simply Wall St · 12/18/2025 17:23
Trump Administration Proposes Rule Banning Medicaid And CHIP From Paying For Gender Affirming Care
Benzinga · 12/18/2025 16:27
FDA Approves Viatris' Generic Sandostatin LAR Depot; To Review Weekly Contraceptive Patch Next July
NASDAQ · 12/18/2025 13:03
Viatris Secures Four Global Regulatory Milestones With FDA Approval Of Octreotide, NDA Review For Estrogen Patch, IND Clearance For MR‑146 Gene Therapy, And PMDA Acceptance Of Pitolisant
Benzinga · 12/18/2025 12:01
FDA Approves Viatris Generic Version of Sandostatin LAR Depot
Reuters · 12/18/2025 11:59
Viatris Provides Pipeline Update on Four Regulatory Milestones
PR Newswire · 12/18/2025 11:59
Viatris Inc. to Present at J.P. Morgan Healthcare Conference
Reuters · 12/17/2025 11:59
Viatris to Present at the 44th Annual J.P. Morgan Healthcare Conference
PR Newswire · 12/17/2025 11:59
More
Webull provides a variety of real-time VTRS stock news. You can receive the latest news about Viatris Inc Ord Shs through multiple platforms. This information may help you make smarter investment decisions.
About VTRS
Viatris Inc. is a global healthcare company. The Company's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment comprises its operations primarily in North America and Europe. The Greater China segment includes its operations in China, Taiwan and Hong Kong. The JANZ segment reflects its operations in Japan, Australia, and New Zealand. The Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies, including in Asia, Africa, Eastern Europe, Latin America, and the Middle East, as well as the Company’s Antiretroviral medicines (ARV) franchise. Its pipeline and research and development capabilities include expertise in formulation, device development, toxicology, analytical, clinical, bioanalytical, medical affairs, product safety and risk management across a range of therapeutic areas. It produces oral solid doses, injectables, and products with complex dosage forms.